Whilst the NPV of BDG (99.9%) and Candida IgM (99.8%) is comparable and within a range acceptable for use in a clinical setting, our data demonstrate that Candida IgM is detectable earlier in the course of infection compared to other biomarkers (Figure 2). This evidence concerns the gene CD40LG and infection.